Next Article in Journal
Changes of Brain Structures and Psychological Characteristics in Predatory, Affective Violent and Nonviolent Offenders
Previous Article in Journal
Image Quality and Radiation Dose of Contrast-Enhanced Chest-CT Acquired on a Clinical Photon-Counting Detector CT vs. Second-Generation Dual-Source CT in an Oncologic Cohort: Preliminary Results
Previous Article in Special Issue
Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience
Article

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer

1
PET Imaging Centre, University Hospital of North Norway, 9019 Tromsø, Norway
2
Department of Diagnostic Imaging and Intervention, AHUS University Hospital, 1478 Lørenskog, Norway
3
Department of Research Support for Clinical Trials, Clinical Trials Unit (CTU), Oslo University Hospital, 0424 Oslo, Norway
4
Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, 8200 Aarhus, Denmark
*
Author to whom correspondence should be addressed.
Academic Editor: Emilio Quaia
Tomography 2022, 8(3), 1477-1484; https://doi.org/10.3390/tomography8030120
Received: 5 May 2022 / Revised: 30 May 2022 / Accepted: 31 May 2022 / Published: 3 June 2022
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)
Background: 18F-fluciclovine is a positron emission tomography (PET) radiotracer approved for the detection of prostate cancer recurrence. No effect of androgen deprivation therapy (ADT) on its performance has been established. Purpose: To study the impact of concurrent ADT on disease detection with 18F-fluciclovine PET in patients with prostate cancer. Materials and Methods: Data from patients with prostate cancer who had been receiving ADT for ≥3 months at the time of undergoing an 18F-fluciclovine PET/CT at our institution were retrospectively reviewed. Seventy-three scans from 71 patients were included. The scans indicated rising prostate-specific antigen (n = 58), staging advanced disease (n = 4) or therapeutic monitoring (n = 9). Patients’ medical records provided baseline clinical data and post-scan outcomes (median follow-up 40 months). Results: Malignant lesions with increased uptake of 18F-fluciclovine were detected in 60/73 (82%) scans; 33 (45%) had lesions in the prostate/bed and 46 (63%) in extraprostatic sites. Patients received ADT for a median of 2 years (range 3 months to >10 years) pre-scan. The time on ADT did not influence detection; the detection rates were 89% for patients who had received ADT for <1 year, 63% for a treatment period of 1–<2 years, 83% for 2–4 years, 78% for >4–10 years, and 67% for a treatment period of >10 years. Conclusion: 18F-fluciclovine detected recurrent or metastatic lesions in 82% of patients with prostate cancer receiving ADT. The rates achieved in the present study are consistent with widely reported data for 18F-fluciclovine PET/CT, suggesting that withdrawal of ADT before scanning is not necessary. View Full-Text
Keywords: PET; prostate cancer; androgen deprivation therapy; fluciclovine PET; prostate cancer; androgen deprivation therapy; fluciclovine
Show Figures

Figure 1

MDPI and ACS Style

Bach-Gansmo, T.; Korsan, K.; Bogsrud, T.V. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer. Tomography 2022, 8, 1477-1484. https://doi.org/10.3390/tomography8030120

AMA Style

Bach-Gansmo T, Korsan K, Bogsrud TV. Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer. Tomography. 2022; 8(3):1477-1484. https://doi.org/10.3390/tomography8030120

Chicago/Turabian Style

Bach-Gansmo, Tore, Katrine Korsan, and Trond V. Bogsrud. 2022. "Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer" Tomography 8, no. 3: 1477-1484. https://doi.org/10.3390/tomography8030120

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop